Welcome to our dedicated page for NRX Pharmaceuticals SEC filings (Ticker: NRXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NRx Pharmaceuticals, Inc. filings document regulatory, governance, financing, and corporate-status disclosures for a clinical-stage biopharmaceutical issuer listed on Nasdaq with common stock and NRXPW warrants. Recent reports include Form 8-K disclosures on FDA-related press releases for NRX-100 ketamine, at-the-market equity offering documentation under a Form S-3 registration statement, officer appointments, Nasdaq listing-rule correspondence, and changes in the company’s independent registered public accounting firm.
The company’s proxy and annual-meeting filings cover director elections, stockholder voting results, executive compensation disclosures, and amendments to the Omnibus Incentive Plan. Acquisition-related amendments provide financial statements and pro forma financial information for Dura Medical after its completed acquisition by HOPE Therapeutics, while other filings address exhibits, legal opinions, capital-structure mechanics, and governance matters tied to the company’s development and commercialization activities.
NRx Pharmaceuticals, Inc. reported financial results for the quarter and six months ended June 30, 2026, alongside a significant corporate update. For the six-month period, the company reported a net loss of $18.0 million compared with $23.1 million in 2025, while net operating loss increased to $11.3 million from $7.6 million due to higher R&D and commercial readiness expenses. Cash and cash equivalents rose to $26.7 million as of June 30, 2026 from $7.8 million at December 31, 2025, primarily driven by a public equity offering with more than $22 million in gross proceeds, supporting at least one year of operations.
The company advanced its ANDA for preservative-free ketamine, with the FDA citing no major drug or manufacturing deficiencies and only one container-related issue, which has been addressed. NRx is manufacturing 5 million units of launch stock with plans for 1 million units per month post-launch, targeting 2026 approval and commercialization. The NDA for NRX-100 is being finalized following federal support for using Real World Evidence, including data from 65,000 patients, with an approval goal in 2027. NRx was also selected as Prime Contractor for the DARPA SPARC-TMS phase 3 trial of NRX-101, potentially expanding its addressable depression market to more than 15 million Americans, and invested in Geneuro, Inc., gaining two clinical-stage monoclonal antibodies for ALS and other neurodegenerative and autoimmune conditions.
NRx Pharmaceuticals, Inc. reported results for the quarter ended June 30, 2026 as a clinical-stage biopharmaceutical company now also generating clinic revenue through its HOPE subsidiary. Net patient service revenue was $1.1 million for the quarter and $2.2 million for the first six months of 2026, compared with none in 2025, reflecting acquired Florida behavioral health clinics.
The company recorded a six‑month net loss of $17.9 million and used $13.2 million of cash in operating activities. Cash and cash equivalents increased to $26.7 million as of June 30, 2026 from $7.8 million at year‑end, driven by $11.8 million raised via at‑the‑market issuances and a $20.7 million underwritten equity offering. Total assets were $34.2 million, offset by $34.3 million of liabilities, including $18.6 million of warrant liabilities and a $5.8 million refund liability to Alvogen.
Stockholders’ deficit narrowed to $0.2 million. Management disclosed that recurring losses, a $4.7 million working capital deficit and funding uncertainties raise substantial doubt about the ability to continue as a going concern, despite current cash projected to support drug development into early 2027.
NRx Pharmaceuticals is updating investors on U.S. FDA review of its Abbreviated New Drug Application (ANDA) for preservative‑free ketamine. On July 30, 2026 the FDA reported no major deficiencies related to the drug components, but requested a label update to match the reference drug Ketalar and identified a single major deficiency concerning the twist‑off cap of the luer lock vial, which affects the container closure.
NRx highlighted performance testing on 3,500 vials from seven manufacturing batches and real‑world experience with 11.9 million doses of similar products using the same vial design, without complaints, returns, or recalls. After an August 6, 2026 clarification meeting, the FDA asked for formal manufacturer certifications that this product is made on the same lines and with the same materials as three approved ANDA products, then agreed to immediately reinitiate review focused on this packaging issue and to complete it in the shortest‑possible review cycle. Management notes ketamine’s presence on the FDA drug shortage list and expresses optimism about resolving the packaging concern and achieving initial commercial sales in 2026, while acknowledging that regulatory outcomes cannot be assured.
NRx Pharmaceuticals, Inc., through its Florida-based subsidiary NRx Defense Systems, Inc., received a July 21, 2026 letter from the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office stating that its proposal for a clinical trial titled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) has been selected for negotiation of a potential award.
The SPARC-TMS study uses robotic-enabled Transcranial Magnetic Stimulation combined with NRX-101 (D-cycloserine/lurasidone) to evaluate remission from depression. The protocol is approved by the FDA as a phase 2/3 trial and is listed on ClinicalTrials.gov as NCT07227103. Planned sites include Harvard McLean Hospital, HOPE Therapeutics clinics, and military treatment facilities such as Walter Reed National Military Medical Center. NRX-101 is patented by the company and previously received FDA Breakthrough Therapy Designation. DARPA’s selection is only for contract negotiations and is not an award, funding commitment, or authorization to incur costs; any award would depend on successfully negotiating definitive terms.
NRx Pharmaceuticals completed an underwritten public offering of 5,714,286 shares of common stock at $3.50 per share, with underwriters granted a 30-day option for 857,142 additional shares. The company expects net proceeds of about $18.8 million, or $21.6 million if the option is fully exercised.
The gross proceeds described in related press releases were approximately $20.0 million at pricing and $22.3 million at closing, including full exercise of the underwriters’ option. NRx plans to use the cash for working capital and general corporate purposes to support its growth. Directors and executives agreed to a 60-day lockup on stock sales.
NRx Pharmaceuticals is offering 5,714,286 shares of Common Stock at $3.50 per share. The underwriters have a 30-day option to purchase up to an additional 857,142 shares. Delivery is expected on or about June 4, 2026. The prospectus states gross proceeds of $20,000,001.00 and estimated net proceeds to the company of approximately $18,800,000.94, or about $21,619,998.12 if the option is fully exercised. The number of shares expected to be outstanding after the offering is 36,228,993 (or 37,086,135 if the option is exercised), based on May 15, 2026 outstanding data.
The offering is being made under a shelf registration on Form S-3 and is a firm commitment underwriting led by BTIG with Lucid Capital Markets as joint bookrunner; net proceeds are stated to be for working capital and general corporate purposes.
NRx Pharmaceuticals, Inc. plans an underwritten public offering of its common stock, using an already effective shelf registration statement on Form S-3. The company also expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold on the same terms. Net proceeds are currently intended for working capital and general corporate purposes to support the company’s growth. The transaction remains subject to market and other conditions, and there is no assurance on completion, timing, or final size.
NRx Pharmaceuticals, Inc. is offering shares of its common stock pursuant to a preliminary prospectus supplement dated June 2, 2026 under its Form S-3 shelf registration. The offering is described as a firm‑commitment, underwritten public offering with an underwriter option exercisable for 30 days; delivery is expected on or about June, 2026, subject to completion.
The prospectus supplement relies on the Base Prospectus from the company’s Form S-3 (File No. 333-288205) and discloses use of proceeds for working capital and general corporate purposes. The supplement cites 36,228,992 shares outstanding as of May 15, 2026 as the baseline share count used to compute pro forma figures.
NRX Pharmaceuticals, Inc. is the subject of a Form 25 notification filed by Nasdaq Stock Market LLC to remove a class of Warrant securities from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with 17 CFR 240.12d2-2 and shows Commission File Number 001-38302. The document includes an expiration reference of March 31, 2018 and lists the issuer's principal office at 1201 Orange Street, Suite 600, Wilmington, DE 19801.
NRx Pharmaceuticals reported a smaller quarterly loss but continues to face serious liquidity pressure. For the three months ended March 31, 2026, the company generated its first significant clinical revenue of $1.1M from HOPE behavioral health clinics but still posted a net loss of $1.4M, improved from a $5.5M loss a year earlier. Cash and cash equivalents were $6.7M with total assets of $11.9M, against total liabilities of $25.7M, resulting in a stockholders’ deficit of $13.8M. Management disclosed a working capital deficit of about $17.8M and explicitly concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least twelve months. The company expects to fund NDA submissions for KETAFREE™, NRX‑100 and NRX‑101 through at least the third quarter of 2026 using existing cash, clinic revenue and an at‑the‑market equity program, while acknowledging uncertainty around future financings and regulatory approvals.